This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Tet2 at the interface between cancer and immunity
Communications Biology Open Access 12 November 2020
-
Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia
Communications Biology Open Access 07 September 2020
-
Hydroxymethylation and tumors: can 5-hydroxymethylation be used as a marker for tumor diagnosis and treatment?
Human Genomics Open Access 06 May 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Delhommeau F, Dupont S, James C, Masse A, le Couedic JP, Valle VD et al. TET2 is a novel tumor suppressor gene inactivated in myeloproliferative neoplasms: identification of a Pre-JAK2 V617F event. ASH Annual Meeting Abstracts 2008; 112: lba-3. Late-Breaking Abstract.
Tefferi A, Pardanani A, Lim K-H, Abdel-Wahab O, Lasho TL, Patel J et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009, advance online publication, 5 March 2009; doi:10.1038/ leu.2009.47.
Tefferi A, Levine RL, Lim K-H, Abdel-Wahab O, Lasho TL, Patel J et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009, advance online publication, 5 March 2009; doi:10.1038/ leu.2009.37.
Tefferi A, Vardiman JW . Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14–22.
Jaffe ES, Harris NL, Stein H, Vardiman JW . World Health Organization Classification of Tumours of Hematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2001, pp 1–351.
Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008; 22: 756–761.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tefferi, A., Lim, KH., Abdel-Wahab, O. et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 23, 1343–1345 (2009). https://doi.org/10.1038/leu.2009.59
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2009.59
This article is cited by
-
TET2 deficiency sensitizes tumor cells to statins by reducing HMGCS1 expression
Oncogene (2022)
-
Hydroxymethylation and tumors: can 5-hydroxymethylation be used as a marker for tumor diagnosis and treatment?
Human Genomics (2020)
-
Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia
Communications Biology (2020)
-
Tet2 at the interface between cancer and immunity
Communications Biology (2020)
-
p53-dependent autophagic degradation of TET2 modulates cancer therapeutic resistance
Oncogene (2019)